GlassScriptPhysician profile
David Flemming
NPI 1093726739
$6,539.88
in general payments reported to CMS, 2019-2025
34 companies · $805 in 2025
The $805 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,606 · 2020: $729 · 2021: $1,032 · 2022: $755 · 2023: $961 · 2024: $653 · 2025: $805.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,410 · Education: $8.82.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,409.97 |
| Education | $8.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,101.61 | 2019-2025 | |
| Pfizer INC. | $772.77 | 2019-2025 | |
| Novo Nordisk INC | $703.87 | 2019-2025 | Ozempic, Rybelsus, Saxenda |
| Takeda Pharmaceuticals U.S.A., INC. | $561.43 | 2019-2023 | Trintellix |
| Amgen INC. | $429.44 | 2019-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $398.28 | 2020-2025 | Mounjaro, Jardiance, Kisunla |
| Merck Sharp & Dohme LLC | $391.65 | 2019-2024 | Belsomra, Capvaxive, Gardasil |
| Astrazeneca Pharmaceuticals LP | $381.30 | 2019-2025 | Farxiga, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $340.59 | 2019-2023 | Synjardy, Jardiance, Trijardy Xr |
| Allergan, INC. | $240.21 | 2019-2020 | |
| Glaxosmithkline, LLC. | $210.75 | 2019-2025 | Shingrix, Arexvy, Boostrix |
| Novartis Pharmaceuticals Corporation | $177.49 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $107.90 | 2019-2022 | |
| Amarin Pharma, INC. | $94.87 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $89.70 | 2019-2021 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $59.20 | 2019-2025 | Zoryve, Seglentis |
| Biohaven Pharmaceutical Holding Company LTD. | $49.11 | 2022 | |
| Astellas Pharma US INC | $48.51 | 2019-2021 | |
| Phathom Pharmaceuticals, INC. | $47.14 | 2024 | Voquezna |
| Exact Sciences Corporation | $43.94 | 2023-2024 | Cologuard Collection Kit |
| Inspire Medical Systems, INC. | $32.62 | 2023 | Inspire |
| Otsuka America Pharmaceutical, INC. | $29.79 | 2023 | Rexulti |
| Idorsia Pharmaceuticals US INC | $28.84 | 2024 | Quviviq |
| Amneal Pharmaceuticals LLC | $26.27 | 2021 | |
| Ironwood Pharmaceuticals, INC | $25.78 | 2019 | |
| Nalpropion Pharmaceuticals LLC | $25.56 | 2019 | |
| Arbor Pharmaceuticals, INC. | $22.92 | 2019 | |
| Lundbeck LLC | $17.18 | 2023 | Rexulti |
| Janssen Pharmaceuticals, INC | $14.33 | 2020 | |
| Eisai INC. | $13.83 | 2021 | |
| Corium, LLC | $13.72 | 2022 | |
| Medtronic, INC. | $13.60 | 2025 | Intellis Adaptivestim |
| Abbott Laboratories | $12.84 | 2022 | |
| Sanofi-Aventis U.S. LLC | $12.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Flemming listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.